| Literature DB >> 28966508 |
Jin Yong Lee1, Kwang Ho Kim2, Ji Eun Hahm1, Jae Won Ha1, Won Joo Kwon2, Chul Woo Kim1, Sang Seok Kim1.
Abstract
BACKGROUND: Plasma cell cheilitis is an unusual benign plasma cell proliferative disease of an unknown etiology that typically presents on the lip.Entities:
Keywords: Chelitis; Kappa chain; Lambda chain; Plasma cells
Year: 2017 PMID: 28966508 PMCID: PMC5597645 DOI: 10.5021/ad.2017.29.5.536
Source DB: PubMed Journal: Ann Dermatol ISSN: 1013-9087 Impact factor: 1.444
Fig. 1(A) The lower lip shows a diffuse dark blue-grayish to erythematous patch with several fissures and hemorrhagic crusts (patient 3). (B) Painful ulcerative lesion is noted on the left lower angle of the lip on a patient who used dentures (patient 9). (C) Prominent edematous erosive lower lip mucosa is shown (patient 10). (D) Multiple well-demarcated erythematous patches with crust formation and marked swelling on the lower lip are identified (patient 6).
Demographic and clinical characteristics of patients with plasma cell cheilitis (n=13)
| Clinical manifestations | Results |
|---|---|
| Mean age (yr) | 64.7 (39~86) |
| Sex | |
| Male | 9 (69.2) |
| Female | 4 (30.8) |
| Location | |
| Upper lip | 0 (0) |
| Lower lip | 13 (100) |
| Clinical presentation | |
| Patch | 8 (61.5) |
| Plaque | 5 (38.5) |
| Accompanied by | |
| Erosion | 10 (76.9) |
| Ulcer | 2 (15.4) |
| Bleeding and crust | 9 (69.2) |
| Swelling or edema | 9 (69.2) |
| Smoking | 7 (53.8) |
| Habitual behavior | |
| Denture | 3 (23.1) |
| Chewing gum | 1 (7.7) |
| Lip biting | 1 (7.7) |
| Associated symptoms | |
| Pricking | 7 (53.8) |
| Pain | 6 (46.2) |
| Pruritus | 3 (23.1) |
| Burning | 2 (15.4) |
Values are presented as number (range) or number (%).
Fig. 2This specimen from the lip shows an epidermal detachment with a dense, band-like infiltrate of plasma cells in the upper dermis. (A) Eosinophilic infiltration within the dermis is also present (H&E, ×100). (B) A high power view shows a monomorphic population of mature plasma cells without cellular atypia, pleomorphic figures, and mitotic activity (H&E, ×400). (C) A diffuse strong positivity for kappa light chain is noted in the plasma cell infiltrates (kappa chain, ×200). (D) Few plasma cells are positive for lambda light chain restriction (lambda chain, ×200).
Histopathological characteristics of patients with plasma cell cheilitis (n=13)
| Histopathological features | Results |
|---|---|
| Acanthosis | 8 (61.5) |
| Papillary edema | 4 (30.8) |
| Parakeratosis | 6 (46.2) |
| Vacuolar degeneration | 8 (61.5) |
| Eosinophilic infiltration | 9 (69.2) |
| Neutrophilic infiltration | 5 (38.5) |
| Infiltration pattern of plasma cells | |
| Band-like | 8 (61.5) |
| Diffuse | 5 (38.5) |
| Kappa chain reactivity* | |
| +++ | 6 (46.2) |
| ++ | 5 (38.5) |
| + | 2 (15.4) |
| – | 0 (0) |
| Lambda chain reactivity* | |
| +++ | 1 (7.7) |
| ++ | 4 (30.8) |
| + | 8 (61.5) |
| – | 0 (0) |
| Kappa predominance | 9 (69.2) |
Values are presented as number (%). *The reactivity levels of kappa and lambda light chains based on the starting intensity were graded as follows: − (negative, no positive cells), + (weak positive, ≤25% positive cells), ++ (moderately positive, 26%~50% positive cells), and +++ (strongly positive, >50% positive cells).
Treatment and outcome of the 13 included patients with plasma cell cheilitis
| Patients no. | Sex/age (yr) | Treatment modalities | Outcome | Follow-up period (mo) |
|---|---|---|---|---|
| 1 | M/82 | Intralesional steroid injection, topical tacrolimus 0.1% | Relapsed | 11 |
| 2 | M/52 | Intralesional steroid injection, topical tacrolimus 0.1% | CR | 6 |
| 3 | M/75 | Intralesional steroid injection, topical tacrolimus 0.1% | PR | 13 |
| 4 | F/75 | Intralesional steroid injection, topical tacrolimus 0.1%, systemic steroid (MPD) | Relapsed | 6 |
| 5 | F/65 | Intralesional steroid injection, topical tacrolimus 0.1%, systemic steroid (MPD) | Relapsed | 5 |
| 6 | M/53 | Intralesional steroid injection, topical tacrolimus 0.03% | CR | 3 |
| 7 | M/65 | Intralesional steroid injection, topical tacrolimus 0.03% | CR | 7 |
| 8 | M/39 | Intralesional steroid injection, topical tacrolimus 0.1% | PR | 4 |
| 9 | F/86 | Intralesional steroid injection, topical steroid, systemic steroid (MPD) | Relapsed | 39 |
| 10 | M/79 | Topical tacrolimus 0.1%, topical steroid | Relapsed | 17 |
| 11 | F/58 | Topical tacrolimus 0.1% | PR | 9 |
| 12 | M/55 | Topical tacrolimus 0.1%, systemic steroid (MPD), cryotherapy | PR | 18 |
| 13 | M/57 | Intralesional steroid injection, topical pimecrolimus, systemic steroid (MPD) | PR | 8 |
M: male, F: female, CR: complete remission, PR: partial remission, MPD: methylprednisolone.